40 results on '"Sulkowski, Mark S"'
Search Results
2. Safety and efficacy of current direct‐acting antiviral regimens in kidney and liver transplant recipients with hepatitis C: Results from the HCV‐TARGET study
3. Sofosbuvir‐velpatasvir with ribavirin for 24 weeks in hepatitis C virus patients previously treated with a direct‐acting antiviral regimen
4. Safety and Efficacy of Ledipasvir-Sofosbuvir in Black Patients with Hepatitis C Virus Infection: A Retrospective Analysis of Phase 3 Data
5. Hepatitis C guidance: AASLD-IDSA recommendations for testing, managing, and treating adults infected with hepatitis C virus
6. Sofosbuvir plus pegylated interferon and ribavirin in patients with genotype 1 hepatitis C virus in whom previous therapy with direct-acting antivirals has failed
7. Concordance of sustained virological response 4, 12, and 24 weeks post-treatment with sofosbuvir-containing regimens for hepatitis C virus
8. Efficacy and safety of MK-5172 + MK-8742 ± ribavirin in HCV mono-infected and HIV/HCV co-infected treatment-naïve, non-cirrhotic patients with hepatitis C virus genotype 1 infection: The C-WORTHY study (Final results, Parts A and B): 236
9. Sofosbuvir and Ribavirin therapy for the Treatment of HIV/HCV coinfected patients with HCV GT1-4 Infection: The PHOTON-1 and -2 Trials: 195
10. Integrated Efficacy Analysis of Four Phase 3 Studies in HCV Genotype 1a-Infected Patients Treated with ABT-450/r/Ombitasvir and Dasabuvir With or Without Ribavirin: 83
11. An Integrated Safety and Efficacy Analysis of >500 Patients with Compensated Cirrhosis Treated with Ledip-asvir/Sofosbuvir with or without Ribavirin: 82
12. Antiretroviral therapy, interferon sensitivity, and virologic setpoint in human immunodeficiency virus/hepatitis C virus coinfected patients
13. All-Oral Combination of Ledipasvir, Vedroprevir, Tegobuvir, and Ribavirin in Treatment-Naïve Patients With Genotype 1 HCV Infection
14. Cost Analysis of Sofosbuvir/Ribavirin Versus Sofosbuvir/Simeprevir for Genotype 1 Hepatitis C Virus in Interferon-Ineligible/Intolerant Individuals
15. Fibrosis progression in human immunodeficiency virus/hepatitis C virus coinfected adults: Prospective analysis of 435 liver biopsy pairs
16. Faldaprevir combined with peginterferon alfa-2a and ribavirin in chronic hepatitis C virus genotype-1 patients with prior nonresponse: SILEN-C2 trial
17. Faldaprevir combined with pegylated interferon alfa-2a and ribavirin in treatment-naïve patients with chronic genotype1 HCV: SILEN-C1 trial
18. Anemia during treatment with peginterferon Alfa-2b/ribavirin and boceprevir: Analysis from the serine protease inhibitor therapy 2 (SPRINT-2) trial
19. In APRICOT and PARADIGM 99% of HIV-HCV coinfected patients with an SVR12 achieved an SVR24 validating SVR12 as an endpoint for trials in this population: 809
20. The Safety of Telaprevir in the Absence of Interferon and/or Ribavirin: Analysis of On-Treatment Data from the ZENITH Trial: 786
21. The NS5A Inhibitor GS-5885 Is Safe and Well-Tolerated in Over 1000 Patients Treated in Phase 2 Studies: 783
22. Assessment of Boceprevir (VICTRELIS™) Pharmacokinetic/Pharmacodynamic Relationships for Sustained Viral Response (SVR) and Occurrence of Anemia: Results in HCV/HIV Co-infected Patients and in Combined Mono- and Co-Infected Patients: 770
23. Daclatasvir, an NS5A Replication Complex Inhibitor, Combined With Peginterferon Alfa-2a and Ribavirin in Treatment-Naive HCV-Genotype 1 or 4 Subjects: Phase 2b COMMAND-1 SVR12 Results: 755
24. Complete SVR4 Rates in Treatment-Naïve HCV Genotype 1a and 1b Patients Who Achieved vRVR with an Interferon-Free All-Oral Regimen: 212
25. Telaprevir in Combination with Peginterferon Alfa-2a/Ribavirin in HCV/HIV Co-infected Patients: SVR24 Final Study Results: 54
26. Refinement of stopping rules during treatment of hepatitis C genotype 1 infection with boceprevir and peginterferon/ribavirin
27. Racial differences in hepatitis C treatment eligibility
28. Challenges in treatment of hepatitis C among patients with hepatocellular carcinoma
29. Glecaprevir and pibrentasvir for 12 weeks for hepatitis C virus genotype 1 infection and prior direct‐acting antiviral treatment
30. Safety and efficacy of ledipasvir‐sofosbuvir in black patients with hepatitis C virus infection: A retrospective analysis of phase 3 data
31. Concordance of sustained virological response 4, 12, and 24 weeks post‐treatment with sofosbuvir‐containing regimens for hepatitis C virus
32. Hepatitis C trials that combine investigational agents with pegylated interferon should be stratified by interleukin-28B genotype
33. Serum cholesterol and statin use predict virological response to peginterferon and ribavirin therapy
34. The effect of antiretroviral therapy on liver disease among adults with HIV and hepatitis C coinfection
35. Defining the standard of care: Randomized controlled trials for the treatment of hepatitis C in the HIV-infected person
36. Treatment of chronic hepatitis C: A systematic review
37. Reply
38. Prevalence of type 2 diabetes mellitus among persons with hepatitis C virus infection in the United States
39. 1125 Hepatotoxicity associated with the antiretroviral therapy (ART) containing protease inhibitors (PIS) with or without pharmacokinetic boosting by low-dose ritonavir (RTV)
40. 551 Projecting the prognosis of hepatic fibrosis in HIV-HCV co-infection
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.